Todavía no hay suficientes señales de compra con un horizonte T+90 consolidado para medir un historial.
Historial de señales
Discover the full record of transactions filed by Fust Matthew K, Consejero. Director active across 5 companies, notably Atara Biotherapeutics, Inc.. Cumulatively, 29 disclosures have been logged. Split: 0 buy · 3 sells. Total volume traded: €957k. Activity tracked since 8 June 2021. The latest transaction was filed on 26 September 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Fust Matthew K
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5000 títulos@ 1,91 US$0.8% de su flujoCommon StockSEC:0001209191-21-048375:0
25 de 29 declaraciones
About Fust Matthew K
Fust Matthew K is Administrateur at Crinetics Pharmaceuticals, Inc., Atara Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Neumora Therapeutics, Inc. He has 29 filings in total, and across the sampled recent filings from 2021-06-09 to 2026-06-22, sales total EUR 957160 and the dominant transaction nature is Attribution.